Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1

Biochemical and Biophysical Research Communications

Volumn 432, Issue 1, 2013, Pages 22-27

  Liu, Yu ^a   Higashitsuji, Hiroaki ^a   Higashitsuji, Hisako ^a   Itoh, Katsuhiko ^a   Sakurai, Toshiharu ^b   Koike, Kazuhiko ^c   Hirota, Kiichi ^d   Fukumoto, Manabu ^e   Fujita, Jun ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

Author keywords

FIH 1; Hemangioma; HIF 1; Oncogene; PSMD10

Indexed keywords

ACTIVATING HYPOXIA INDUCIBLE FACTOR 1; DIETHYLNITROSAMINE; FACTOR INHIBITING HYPOXIA INDUCIBLE FACTOR 1; GANKYRIN; HEPATITIS B VIRUS X PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ONCOPROTEIN; SERUM AMYLOID P; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE OVEREXPRESSION; HEMANGIOMA; IN VIVO STUDY; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VASCULAR TUMOR; VASCULARIZATION; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HEMANGIOMA; HEMANGIOSARCOMA; HEPATOCYTES; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; MIXED FUNCTION OXYGENASES; NEOVASCULARIZATION, PATHOLOGIC; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

HEPATITIS B VIRUS; MUS; MUS MUSCULUS;

EID: 84875372801     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.093     Document Type: Article

References (22)

1. Higashitsuji H., Itoh K., Nagao T., et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 2000, 6:96-99.
2. Besche H.C., Peth A., Goldberg A.L. Getting to first base in proteasome assembly. Cell 2009, 138:25-28.
3. Krzywda S., Brzozowski A.M., Higashitsuji H., et al. The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. J. Biol. Chem. 2004, 279:1541-1545.
4. Higashitsuji H., Higashitsuji H., Itoh K., et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005, 8:75-87.
5. Higashitsuji H., Higashitsuji H., Liu Y., et al. The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity. Biochem. Biophys. Res. Commun. 2007, 363:879-884.
6. Sun W., Ding J., Wu K., et al. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. Hepatology 2011, 54:1259-1272.
7. Fu J., Chen Y., Cao J., et al. P28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology 2011, 53:181-192.
8. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
9. Koh M.Y., Powis G. Passing the baton: the HIF switch. Trends Biochem. Sci. 2012, 37:364-372.
10. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15:2586-2675.
11. Koike K., Moriya K., Ishibashi K., et al. Expression of hepatitis C virus envelope proteins in transgenic mice. J. Gen. Virol. 1995, 76:3031-3038.
12. Araki K., Hino O., Miyazaki J., Yamamura K. Development of two types of hepatocellular carcinoma in transgenic mice carrying the SV40 large T-antigen gene. Carcinogenesis 1991, 12:2059-2062.
13. Semenza G.L., Jiang B.H., Leung S.W. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271:32529-32537.
14. Umemura A., Itoh Y., Itoh K., et al. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology 2008, 47:493-502.
15. Jiang B.H., Zheng J.Z., Leung S.W., et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. J. Biol. Chem. 1997, 272:19253-19260.
16. Wilkins S.E., Karttunen S., Hampton-Smith R.J., et al. Factor inhibiting HIF (FIH) recognizes distinct molecular features within hypoxia-inducible factor-α (HIF-α) versus ankyrin repeat substrates. J. Biol. Chem. 2012, 287:8769-8781.
17. Harada T., Enomoto A., Boorman G.A., Maronpot R.R. Liver and gallbladder. Pathology of the Mouse 1999, 119-183. Cache River Press, Vienna, IL. R.R. Maronpot (Ed.).
18. Cohen S.M., Storer R.D., Criswell K.A., et al. Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol. Sci. 2009, 111:4-18.
19. Leppänen P., Kholová I., Mähönen A.J., et al. Short and long-term effects of hVEGF-A(165) in Cre-activated transgenic mice. PLoS One 2006, 1:e13.
20. Springer M.L., Banfi A., Ye J., et al. Localization of vascular response to VEGF is not dependent on heparin binding. FASEB J. 2007, 21:2074-2085.
21. Oladipupo S., Hu S., Kovalski J., et al. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc. Natl. Acad. Sci. USA 2011, 108:13264-13269.
22. Shin D.H., Li S.H., Yang S.W., et al. Inhibitor of nuclear factor-kappaB alpha derepresses hypoxia-inducible factor-1 during moderate hypoxia by sequestering factor inhibiting hypoxia-inducible factor from hypoxia-inducible factor 1alpha. FEBS J. 2009, 276:3470-3480.